Dermatology Clinical Trials

Aesthetic outcome of tie-over bolster application in surgical wounds: a randomized evaluator-blinded split-wound comparative effectiveness trial

Primary Investigator: Daniel Eisen, M.D.
Contact: Salsala Nasim, sanasim@health.ucdavis.edu 
Participant Criteria:

• At least 18 years old
• Scheduled for cutaneous surgical procedure on the head or neck with predicted primary closure
• Willing to return for a follow-up visit

Enrollment: Ongoing until September 2025

Aesthetic outcome of intra-dermal versus transcutaneous purse-string closure: a randomized evaluator-blinded split-wound comparative effectiveness trial

Primary Investigator: Daniel Eisen, M.D.
Contact: Salsala Nasim, sanasim@health.ucdavis.edu 
Participant Criteria:

• At least 18 years old
• Scheduled for cutaneous surgical procedure on the head, neck, trunk or extremities with predicted purse-string closure

Enrollment: Ongoing until December 2027

A phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata

Primary Investigator: Emmanuel Mavrakis, M.D.
Contact: Lauren Downing, ladowning@health.ucdavis.edu 
Participant Criteria:

• Individuals ages 12-64 at baseline 
• Diagnosis of severe alopecia areata with severity of alopecia tool (SALT) score of at least 50 scalp hair loss at screening and baseline
• Severe alopecia areata with no spontaneous scalp hair regrowth over the past 6 months
• Current episode of alopecia areata of less than 8 years

Enrollment: Adult enrollment is closed. Adolescent enrollment is expected to close by the end of 2025.

Pilot study on intralesional cyclosporine for alopecia areata

Primary Investigator: Oma Agbai, M.D.
Contact: Salsala Nasim, sanasim@health.ucdavis.edu 
Participant Criteria:

• Aged 18-65 at screening visit
• Diagnosis of alopecia areata by a board-certified dermatologist at screening visit
• Current alopecia areata episode that involves the scalp of more than 3 months' duration (prior to baseline visit)
• SALT score between 10 and 50 at baseline visit
• Agree not to use any alopecia areata treatments during the study

Enrollment: Ongoing until December 2026

A study to learn about medicine called ritlecitinib in children aged between 6 to 12 years with severe alopecia areata

Primary Investigator: Emmanuel Mavrakis, M.D.
Contact: Jordan Nava, jonava@health.ucdavis.edu 
Participant Criteria:

• Ages 6-12
• A diagnosis of alopecia areata with at least 50% scalp hair loss due to alopecia areata (i.e., SALT score of 50 or greater) at both screening and baseline visits, without evidence of terminal hair regrowth within the previous 12 months

Enrollment: Ongoing until January 2027

USCLC National Cutaneous Lymphoma Registry

Primary Investigator: Peggy Wu, M.D.
Contact: Salsala Nasim, sanasim@health.ucdavis.edu 
Participant Criteria:

• All ages
• Patients living with cutaneous lymphoma

Enrollment: Ongoing

A multicenter, randomized, double-blind, placebo-controlled study to evaluate efficacy, pharmacokinetics, and safety of repeat subcutaneous doses of FB825 in adults with moderate-to-severe atopic dermatitis

Primary Investigator: Victor Huang, M.D.
Contact: Salsala Nasim, sanasim@health.ucdavis.edu 
Participant Criteria:

• Ages 18-65
• Diagnosis of moderate-to-severe atopic dermatitis
• Eczema Area and Severity Index (EASI) score greater than or equal to 16
• Greater than 10% body surface area
• History of inadequate response to a stable (i.e., 4-week) regimen of topical corticosteroids (TCI) or topical calcineurin inhibitors (TCS) as treatment for atopic dermatitis within 6 months before the screening visit

Enrollment: Ongoing until March 2026

A phase 3, multi-center trial to evaluate the efficacy and safety of tralokinumab in combination with topical corticosteroids in children (age 2 to <12 years) and infants (age 6 months to <2 years) with moderate-to-severe atopic dermatitis

Primary Investigator: Smita Awasthi, M.D.
Contact: Jordan Nava, jonava@health.ucdavis.edu 
Participant Criteria:

• Pediatric patient ages 6 months to less than 12 years old at screening
• An EASI score of greater than or equal to 16 at screening and baseline
• Atopic dermatitis involvement of greater than or equal to 10% body surface area at screening and baseline
• Diagnosis of atopic dermatitis as defined by the Hanifin and Rajka criteria

Enrollment: Ongoing until June 2026

Dermatitis quality of life assessment pre- and post-patch testing questionnaire

Primary Investigator: Peggy Wu, M.D.
Contact: Jasmin Johl, jesjohl@health.ucdavis.edu
Participant Criteria:

• Patients referred to UC Davis Health Department of Dermatology for evaluation of rash or dermatitis

Enrollment: Ongoing

A systematic assessment of patch testing outcomes

Primary Investigator: Peggy Wu, M.D.
Contact: Jasmin Johl, jesjohl@health.ucdavis.edu
Participant Criteria:

• Patients referred to UC Davis Health Department of Dermatology for evaluation of rash or dermatitis
• All ages, including those younger than 18 with parental consent

Enrollment: Ongoing

Genetic aberrations driving cutaneous disease

Primary Investigator: Maija Kiuru, M.D.
Contact: Salsala Nasim, sanasim@health.ucdavis.edu 
Participant Criteria:

• Subjects with an active cutaneous, hair or nail disease confirmed by a dermatologist
• 18 years of age or older
• Younger than age 18 with informed consent provided by legal guardian. Only buccal swab for DNA isolation will be performed. 

Enrollment: Ongoing

A Phase 3 randomized, placebo-controlled, double-blind study to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with moderate-to-severe hidradenitis suppurativa who have failed anti-TNF therapy 

Primary Investigator: Emmanuel Mavrakis, M.D.
Contact: Lauren Downing, ladowning@health.ucdavis.edu 
Participant Criteria:

• Individuals ages 12 and older with moderate-to-severe hidradenitis suppurativa
  
• Documented history of previous use of greater than or equal to 1 tumor necrosis factor (TNF) inhibitor for hidradenitis suppurativa for at least 12 weeks and/or 1 approved non-anti-TNF biologic therapy for hidradenitis suppurativa for at least 16 weeks characterized by inadequate response or for any duration characterized by intolerance as determined by the investigator
• Participant must have a total abscess and inflammatory nodule (AN) count of greater than or equal to 5 at baseline
• Hidradenitis suppurativa lesions must be present in at least two distinct anatomic areas at baseline

Enrollment: Ongoing until December 2025

Ethyl chloride spray to reduce pain from local anesthesia during Mohs micrographic surgery

Primary Investigator: Daniel Eisen, M.D.
Contact: Salsala Nasim, sanasim@health.ucdavis.edu 
Participant Criteria:

• At least 18 years old
• Scheduled for Mohs micrographic surgery
• Pre-operative tumor size of at least 1.5 cm

Enrollment: Ongoing until December 2025

Undermining apices in surgical wounds: a randomized evaluator-blinded split-wound comparative effectiveness trial

Primary Investigator: Daniel Eisen, M.D.
Contact: Salsala Nasim, sanasim@health.ucdavis.edu 
Participant Criteria:

• At least 18 years old
• Scheduled for cutaneous surgical procedure on the neck, trunk and extremities with predicted primary closure

Enrollment: Ongoing until December 2026

Barbed versus traditional suture for repair of dermatologic surgery defects: a randomized evaluator-blinded split-wound comparative effectiveness trial

Primary Investigator: Daniel Eisen, M.D.
Contact: Salsala Nasim, sanasim@health.ucdavis.edu 
Participant Criteria:

• At least 18 years old
• Scheduled for cutaneous surgical procedure on the neck, trunk and extremities with predicted primary closure
• Able to give informed consent themselves

Enrollment: Ongoing until December 2027

Effect of pre-operative consultation on patient anxiety and satisfaction following first-time Mohs micrographic surgery

Primary Investigator: Daniel Eisen, M.D.
Contact: Salsala Nasim, sanasim@health.ucdavis.edu 
Participant Criteria:

• At least 18 years old
• Fluent in English
• Presenting for first-time Mohs micrographic surgery for treatment of a cutaneous malignancy

Enrollment: Ongoing until December 2027

Genetic basis of melanocytic nevi

Primary Investigator: Maija Kiuru, M.D.
Contact: Salsala Nasim, sanasim@health.ucdavis.edu 
Participant Criteria:

• Subjects with melanocytic nevi
• 18 years of age and older
• 5 years of age and older (individuals with RASopathy only)

Enrollment: Ongoing

A phase 1/2, open-label, safety and dosing study of autologous CAR T cells (desmoglein 3 chimeric autoantibody receptor T cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T cells [CABA-201]) in subjects with active, pemphigus vulgaris

Primary Investigator: Emmanuel Mavrakis, M.D.
Contact: Lauren Downing, ladowning@health.ucdavis.edu 
Participant Criteria:

• Individuals ages 18 and older 
  
• Confirmed diagnosis of mean platelet volume by prior or screening biopsy and prior positive anti-DSG3 antibody ELISA
• Mean platelet volume inadequately managed by at least one standard immunosuppressive therapy
• Active mean platelet volume at screening
• Anti-DSG3 antibody ELISA positive at screening; inclusion criteria for CABA-201 sub-study
• Pemphigus vulgaris inadequately managed by at least one standard immunosuppressive therapy
• Active pemphigus vulgaris at screening
• DSG3 ELISA positive at screening

Enrollment: Ongoing

Biomarker expression in an adhesive patch-based assay for pigmented lesions

Primary Investigator: Maija Kiuru, M.D.
Contact: Salsala Nasim, sanasim@health.ucdavis.edu 
Participant Criteria:

• At least 18 years old
• Subject must have one of the following:
  • At least one pigmented lesion that is greater than or equal to 4 mm in diameter
  • A pigmented lesion that is confirmed to be melanoma to serve as a control
  • An area of skin without a pigmented lesion to serve as a control
• If the subject has multiple pigmented lesions, the lesions must be at least 4 mm apart

Enrollment: Ongoing until December 2027

A study to determine the effect of a 6-week healthy nutrition intervention on qualitative and objective markers of inflammation in patients with psoriasis

Primary Investigator: Samuel Hwang, M.D.
Contact: Salsala Nasim, sanasim@health.ucdavis.edu 
Participant Criteria:

• At least 18 years old
• History of psoriasis of at least 3% body surface area
• A BMI of 25 or greater
• Recruited patients must habitually consume a Western-type diet

Enrollment: Ongoing until June 2026

A study to conduct ongoing investigations to elucidate the pathogenesis behind local and systemic inflammation in patients with psoriasis through blood and skin samples

Primary Investigator: Samuel Hwang, M.D.
Contact: Salsala Nasim, sanasim@health.ucdavis.edu 
Participant Criteria:

• At least 18 years old
• A diagnosis of psoriasis or atopic dermatitis as determined by a doctor OR a patient who is a health control who has not been diagnosed with psoriasis or atopic dermatitis

Enrollment: Ongoing

Clinical impact of sleep-targeting interventions in psoriasis patients

Primary Investigator: Victor Huang, M.D.
Contact: Morgan Danielle Murry, mdmurry@health.ucdavis.edu 
Participant Criteria:

• At least 18 years old
• Diagnosis of psoriasis as determined by a dermatologist
• Is untreated or receiving skin-directed therapy only (topicals or phototherapy)
• Has adhered to a stable psoriasis management plan for the past two months
• Has a Pittsburgh sleep quality index (PSQI) score of 5 or greater, which correlates with poor sleep

Enrollment: Ongoing until December 2027

A phase 3b/4 multi-center, randomized, open-label, long-term safety study of deucravacitinib in comparison to ustekinumab in participants with moderate-to-severe plaque psoriasis

Primary Investigator: Emmanuel Mavrakis, M.D.
Contact: Jordan Nava, jonava@health.ucdavis.edu 
Participant Criteria:

• At least 40 years old
• Diagnosis of moderate-to-severe plaque psoriasis
• Have at least one of the following cardiovascular risk factors:
  • Current cigarette smoker
  • Diagnosis of hypertension
  • Diagnosis of hyperlipidemia
  • Diagnosis of diabetes Type 1 or 2 
  • Diagnosis of obesity
  • Family history of premature coronary heart disease
  • History of one or more cardiovascular events, including coronary intervention (PCI) or coronary artery bypass grafting (CABG), myocardial infarction (heart attack), cardiac arrest, hospitalization for unstable angina, acute coronary syndrome, stroke or transient ischemic attack

Enrollment: Ongoing until June 2026

A systematic assessment of vitiligo outcomes – a patient registry study

Primary Investigator: Victor Huang, M.D.
Contact: Salsala Nasim, sanasim@health.ucdavis.edu 
Participant Criteria:

• Patients referred to UC Davis Health Department of Dermatology for vitiligo diagnosis and treatment

Enrollment: Ongoing

Analysis of sebaceous tumors derived from subjects with Muir-Torre syndrome or Lynch syndrome or hereditary non-polyposis colorectal cancer

Primary Investigator: Maija Kiuru, M.D.
Contact: Salsala Nasim, sanasim@health.ucdavis.edu 
Participant Criteria:

• At least 18 years old
• Subjects with a sebaceous tumor and MSH2/MSH6/MLH1 deficiency identified with immunohistochemistry
• AND/OR
• Subjects with a sebaceous tumor and diagnosis of Muir-Torre syndrome or Lynch syndrome or hereditary non-polyposis colorectal cancer syndrome

Enrollment: Ongoing until December 2028